Spero Therapeutics, Inc. (NASDAQ:SPRO) CEO Sath Shukla Sells 155,333 Shares

Spero Therapeutics, Inc. (NASDAQ:SPRO) CEO Sath Shukla sold 155,333 shares of the company’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $0.78, for a total transaction of $121,159.74. Following the completion of the transaction, the chief executive officer now owns 1,736,883 shares in the company, valued at approximately $1,354,768.74. The trade was a 8.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Spero Therapeutics Trading Down 5.2 %

NASDAQ:SPRO opened at $0.82 on Friday. The company’s 50-day moving average price is $0.99 and its 200-day moving average price is $1.19. The company has a market cap of $44.62 million, a P/E ratio of 11.69 and a beta of 0.61. Spero Therapeutics, Inc. has a twelve month low of $0.74 and a twelve month high of $1.89.

Analyst Ratings Changes

Several research firms have recently weighed in on SPRO. Evercore ISI cut Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price target on the stock. in a report on Friday, December 20th. TD Cowen reissued a “hold” rating on shares of Spero Therapeutics in a research note on Monday, November 18th. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Spero Therapeutics in a research report on Thursday, January 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, November 15th.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.